Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04540237
Other study ID # Mastitis cytokine
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date January 1, 2021

Study information

Verified date January 2021
Source Istanbul Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying etiologies, including infectious and non-infectious causes. Etiological reasons were examined in various studies, but neither etiology nor definite criteria for diagnosis were found. Our aim in this study is to examine the role of cytokines in differentiating the etiology of granulomatous mastitis and using it as a prognostic marker.


Description:

Granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying aetiology, including infectious and non-infectious causes. This disease can clinically and radiographically mimic breast cancer, which can pose a diagnostic challenge as well as concern during evaluation. A nonspecific inflammatory response, 'granuloma' is defined as necrosis or infiltration of other inflammatory leukocytes, with or without mononuclear phagocyte collection. It is thought to be caused by infectious agents or foreign substances that activate the immune system, leading to granuloma formation. Some of the known inflammatory etiologies of granulomatous mastitis are autoimmune diseases such as tuberculosis (most commonly caused by Mycobacterium tuberculosis), sarcoidosis, fungal infection and granulomatosis with polyangiitis and giant cell arteritis. These diseases cannot be distinguished clinically, pathologically, and radiographically from idiopathic granulomatous mastitis.In this study, we aimed to investigate IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 levels in patients with granulomatous mastitis and to evaluate the differences in cytokine levels and its usability as a predictive marker in diagnosis.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 1, 2021
Est. primary completion date January 1, 2021
Accepts healthy volunteers
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with granulomatous mastitis Exclusion Criteria: - Cancer Patients - Patients with known immunodeficiency - Pregnancy - Patient diagnosed with tuberculosis

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Flow-cytometric analysis
Flow-cytometric analysis of IL-1ß, IFN-a2, IFN-?, TNF-a, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33

Locations

Country Name City State
Turkey Ufuk Oguz Idiz Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Barreto DS, Sedgwick EL, Nagi CS, Benveniste AP. Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings. Breast Cancer Res Treat. 2018 Oct;171(3):527-534. doi: 10.1007/s10549-018-4870-3. Epub 2018 Jul 3. Review. — View Citation

Skandarajah A, Marley L. Idiopathic granulomatous mastitis: a medical or surgical disease of the breast? ANZ J Surg. 2015 Dec;85(12):979-82. doi: 10.1111/ans.12929. Epub 2014 Nov 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cytokine levels IL-1ß, IFN-a2, IFN-?, TNF-a, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 levels 3 months
See also
  Status Clinical Trial Phase
Completed NCT04596046 - Could Intralesional Steroid be the Novel Treatment for Granulomatous Mastitis? N/A
Recruiting NCT02959580 - Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis Phase 4
Recruiting NCT03766997 - Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM) Phase 4
Completed NCT04543149 - Immune Cells in Patients With Granulomatous Mastitis
Completed NCT03724903 - Ductal Lavage Versus Corticosteroids Therapy for Idiopathic Granulomatous Mastitis N/A